Progress in the treatment of advanced gastric cancer

Tumor Biology - Tập 39 Số 7 - Trang 101042831771462 - 2017
Zheyu Song1, Yuanyu Wu1, Jiebing Yang2, Dingquan Yang1, Xuedong Fang1
1Department of General Surgery, China–Japan Union Hospital of Jilin University, Changchun, People’s Republic of China
2Key Laboratory for Molecular Enzymology and Engineering of Ministry of Education, School of Life Sciences, Jilin University, Changchun, People’s Republic of China

Tóm tắt

Gastric cancer is one of the most common malignant tumors in the digestive system. Surgery is currently considered to be the only radical treatment. As surgical techniques improve and progress is made in traditional radiotherapy, chemotherapy, and the implementation of neoadjuvant therapy, the 5-year survival rate of early gastric cancer can reach >95%. However, the low rate of early diagnosis means that most patients have advanced-stage disease at diagnosis and so the best surgical window is missed. Therefore, the main treatment for advanced gastric cancer is the combination of neoadjuvant chemoradiotherapy, molecular-targeted therapy, and immunotherapy. In this article, we summarize several common methods used to treat advanced gastric cancer and discuss the progress made in the treatment of gastric cancer in detail. Only clinical practice and clinical research will allow us to prolong the survival time of patients and allow the patients to truly benefit by paying attention to the individual patient characteristics, drug choice, and developing a reasonable and comprehensive treatment plan.

Từ khóa


Tài liệu tham khảo

10.1002/1097-0142(19821115)50:10<1979::AID-CNCR2820501002>3.0.CO;2-D

10.4132/jptm.2017.01.24

Li B, 2015, Int J Clin Exp Med, 8, 21442

Sun Z, 2015, Int J Clin Exp Med, 8, 21358

Wu H, 2015, Int J Clin Exp Med, 8, 17634

Yoshikawa T, 2016, Gan To Kagaku Ryoho, 43, 1157

10.1136/bmjgast-2016-000095

Lv X, 2015, Int J Clin Exp Med, 8, 19030

Chen Y, 2015, Int J Clin Exp Med, 8, 7728

10.1111/apm.12642

Funaki H, 2016, Gan To Kagaku Ryoho, 43, 1421

10.1200/JCO.1989.7.9.1318

Mai M, 1994, Gan To Kagaku Ryoho, 21, 431

10.1002/(SICI)1097-0142(19970501)79:9<1767::AID-CNCR19>3.0.CO;2-W

10.1023/A:1011611821258

10.1002/1097-0142(20010301)91:5<918::AID-CNCR1081>3.0.CO;2-W

Mirza A, 2013, Int J Surg Oncol, 2013, 781742

10.4166/kjg.2016.68.5.245

10.21037/jgo.2016.05.06

10.1038/bjc.2016.252

10.1016/S0140-6736(69)92326-5

10.1016/j.ijrobp.2007.09.055

10.1016/j.ijrobp.2013.02.008

10.3857/roj.2016.01942

10.1093/jrr/rrw044

Gao P, 2017, Minerva Med, 108, 74

Shen Z, 2015, Int J Clin Exp Med, 8, 6773

Zhang ZZ, 2015, Int J Clin Exp Med, 8, 3700

Chen G, 2014, Int J Clin Exp Med, 7, 5947

Wu Y, 2015, Int J Clin Exp Med, 8, 3595

Huang J, 2014, Int J Clin Exp Med, 7, 3037

10.3748/wjg.v12.i21.3297

10.2174/092986706779026174

10.1053/sonc.2002.35642

10.1188/04.CJON.163-168

10.1038/sj.bjc.6605521

10.1016/S1470-2045(13)70096-2

10.1016/j.jss.2016.09.004

10.18632/oncotarget.14467

Lv Y, 2016, J BUON, 21, 1466

10.1200/JCO.2006.08.0887

10.1200/JCO.2011.36.2236

10.1016/j.ejca.2011.04.006

10.1200/JCO.2009.27.7988

10.1007/s12032-016-0754-8

10.1016/j.ajpath.2015.01.008

Jung CP, 2001, Clin Cancer Res, 7, 2527

Jung C, 2003, Clin Cancer Res, 9, 6052

Motwani M, 2003, Mol Cancer Ther, 2, 549

10.1016/j.intimp.2016.07.002

10.4238/gmr.15027078

10.1111/j.1349-7006.2002.tb01326.x

10.1007/s00432-016-2330-1

10.3892/ol.2016.5189

Tang W, 2015, Int J Clin Exp Med, 8, 8086

10.1159/000460504

10.4251/wjgo.v7.i8.95

10.1007/s00253-012-4034-z

Kanazawa M, 2004, Gan To Kagaku Ryoho, 31, 1773

He W, 2015, Int J Clin Exp Med, 8, 13657

Tang HN, 2015, Int J Clin Exp Med, 8, 10321

Canyilmaz E, 2014, Int J Clin Exp Med, 7, 2656

10.1016/j.bpg.2016.06.006

Thông tin
Thông tin xuất bản

Tumor Biology

Tập 39 Số 7

101042831771462

Thông tin tác giả